News

The $20 Million Bet on CRISPR to Cure Rare Childhood Diseases
Rare genetic diseases are challenging for patients and their families—made all the more overwhelming because symptoms tend to ...
Novartis gets approval for first malaria drug for babies and children
Novartis on Tuesday said it had received approval in Switzerland for Coartem Baby, which it said was the first drug to treat ...
American kids have become increasingly unhealthy over nearly two decades, new study finds
A study shows that the health of U.S. children has deteriorated over the last 17 years, with kids today more likely to ...
BioPharma Dive18h
After delay, Kalvista wins FDA OK for drug to treat rare swelling disorder
The company had blamed FDA "resource constraints" for the delay, while a rival drug for hereditary angioedema received an ...
Scientific American19h
Massive Study Flips Our Story of Addiction and the Brain
Brain differences in children and teens who experiment with drugs early show up before they take their first puff or sip ...
America Facing 'Crisis in Child Health', Doctors Warn
But now is not the time to retreat into our homes to "protect" our children, pediatrician Dr. Christopher Forrest told ...
Dermatology Advisor20h
Benlysta Autoinjector Approved for Pediatric Patients with Lupus Nephritis
The FDA has approved Benlysta for SC administration using an autoinjector in patients 5 years of age and older with active LN.
Pharmaceutical Technology on MSN20h
FDA approves KalVista’s Ekterly for hereditary angioedema
The US Food and Drug Administration (FDA) has approved KalVista Pharmaceuticals' Ekterly (sebetralstat) as the first and only ...
Fierce Pharma20h
KalVista bounces back from FDA delay with approval for oral rare disease med Ekterly
After facing an unexpected regulatory delay last month, KalVista Pharmaceuticals has leapt into the commercial realm with the ...
US FDA approves KalVista's oral swelling disorder drug, shares rise
KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug, the first on-demand oral treatment for a type of hereditary swelling disorder, sending its shares ...